APSR2026-395

Yes
Late-Breaking
Submitted
Oral Presentation
AO14-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1220018-46903-AO14-002. pptx_440592.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nor Safiqah Sharil * University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia Universiti Sains Islam Malaysia Internal Medical Unit, Faculty of Medicine and Health Science Nilai Malaysia
Nafiz Ahmed - University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
Boon Hau Ng - University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
Nik Nuratiqah Nik Abeed - University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
Rose Azzlinda Osman - University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
Marilyn Umar - Ministry of Health Malaysia Non-Communicable Disease Control Programme Center, Sarawak Health Department Sarawak Malaysia
Andrea Yu-Lin Ban - University Kebangsaan Malaysia, Hospital Canselor Tuanku Muhriz Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
 
 
 
 
 
 
 
 
Presenting Author Details
Nor Safiqah
Sharil
n.safiqah@gmail.com
+60172449006
31-40
Malaysia
Original Research
Polypharmacy Drives Risk of Anti-Tuberculosis Drug-Induced Liver Injury: Real-World Evidence from Malaysia
Maximum 25 words
Abstract Content
Drug-induced liver injury (DILI) is a major complication of first-line anti-tuberculosis (TB) therapy that may lead to treatment interruption, increased morbidity, and prolonged hospitalisation. Data describing the prevalence and clinical predictors of anti-TB hepatotoxicity in Malaysian populations remain limited.
We conducted a retrospective cohort study at Hospital Canselor Tuanku Muhriz, Malaysia. Adult patients initiated on first-line anti-TB therapy between 2016 and 2025 with normal baseline liver function were included. Demographic, clinical, comorbidity, and biochemical variables were retrieved from medical records. DILI was defined according to American Thoracic Society criteria. Associations between variables and DILI were analysed using chi-square and Mann–Whitney U tests. Independent predictors were identified using multivariable logistic regression.
Among 300 patients analysed, DILI developed in 22.7% (68/300). Sociodemographic factors including age, sex, ethnicity, body weight, and smoking status were not independently associated with hepatotoxicity. Polypharmacy emerged as the strongest predictor of DILI. Patients receiving ≥5 concomitant medications had nearly a fivefold increased risk of hepatotoxicity (adjusted OR 4.88, 95% CI 1.28–18.59, p=0.020). Pulmonary TB (aOR 0.34, 95% CI 0.14–0.86, p=0.022), outpatient management (aOR 0.11, 95% CI 0.02–0.71, p=0.020), and dyslipidaemia (aOR 0.34, 95% CI 0.12–0.97, p=0.044) were associated with lower odds of DILI. Baseline biochemical parameters, including liver enzymes and lipid profile, were not independent predictors.
Risk stratification for anti-TB DILI should prioritise treatment complexity rather than demographic or baseline biochemical factors, supporting early intervention in patients exposed to multiple concomitant drugs.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tuberculosis; Drug-induced liver injury; Polypharmacy
maximum 3 keywords and no abbreviations, separated by commas
 
261